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Perivascular mesenchymal stem and progenitor cells
(MSPCs) are critical for forming a healthy hematopoi-
etic stem cell (HSC) niche. However, the interactions
and influence of acute myelogenous leukemia (AML)
stem cells with the microenvironment remain largely
unexplored. We have unexpectedly found that neu-
ropathy of the sympathetic nervous system (SNS)
promotes leukemic bone marrow infiltration in an
MLL-AF9 AML model. Development of AML disrupts
SNS nerves and the quiescence of Nestin+ niche
cells, leading to an expansion of phenotypic MSPCs
primed for osteoblastic differentiation at the expense
of HSC-maintaining NG2+ periarteriolar niche cells.
Adrenergic signaling promoting leukemogenesis is
transduced by the b2, but not b3, adrenergic recep-
tor expressed on stromal cells of leukemic bone
marrow. These results indicate that sympathetic
neuropathy may represent a mechanism for the
malignancy in order to co-opt the microenvironment
and suggest separate mesenchymal niche activities
for malignant and healthy hematopoietic stem cells
in the bone marrow.
INTRODUCTION
Understanding the mechanisms by which the hematopoietic
stem cell (HSC) niche regulates leukemia-initiating cells, also
referred to as leukemia stem cells (LSCs), in acute myelogenous
leukemia (AML) is crucial to improving treatment outcome and
eradicating the disease. Expansion of the leukemic clone is
associated with the impairment of normal hematopoiesis, result-
ing in severe anemia, thrombocytopenia, and immunodefi-
ciency, which can lead to severemorbidity in affected individuals
(reviewed in Ferrara and Schiffer, 2013). Additionally, a high
relapse rate in AML suggests that quiescent LSCs are not tar-Cell Sgeted by currently used treatment protocols (Byrd et al., 2002;
Ishikawa et al., 2007). However, little is known about the under-
lying mechanisms that cause the severe hematopoietic failure in
AML and how LSCs alter the bone marrow microenvironment.
Recent studies have demonstrated that healthy HSCs reside
in specific perivascular bone marrow niches, which tightly
regulate their function (reviewed in Frenette et al., 2013). Several
candidate niche cells have been suggested, including CXCL12-
abundant reticular cells (Sugiyama et al., 2006), Nestin+ (Nes+)
cells (Me´ndez-Ferrer et al., 2010), and Leptin receptor (LepR)+
cells (Ding et al., 2012), that exhibit significant overlap among
each other (Pinho et al., 2013). Vascular structures were recently
found to form distinct niches where arterioles marked by Nes-
GFPbright NG2+ pericytes were associated with dormant HSCs,
whereas reticular-shaped sinusoidal Nes-GFPdim cells were
associated with less-quiescent HSCs (Kunisaki et al., 2013).
Arterioles of the bone marrow are highly innervated by neural
fibers of the sympathetic nervous system (SNS) that regulate
HSC migration (Katayama et al., 2006; Me´ndez-Ferrer et al.,
2008). Input from SNS nerves is also critical for bone marrow
regeneration after genotoxic insults where SNS neuropathy
can impair HSC recovery after irradiation or 5-fluorouracil-
induced damage (Lucas et al., 2013).
To what extent LSCs share properties with healthy HSCs re-
mains unclear. Furthermore, the heterogeneity among acute
leukemias suggests the potential for differential requirements
by the bone marrow microenvironment. In keeping with this
idea, expression of different cytokines in the bone marrow can
direct human MLL-AF9 leukemia into either AML or B cell acute
lymphogenous leukemia (ALL) fate (Wei et al., 2008). MLL-AF9
AML cells have been suggested to home further away from the
bone in comparison to healthy HSCs and do not rely on niche-
derived Wnt signals (Lane et al., 2011). In a xenograft model of
ALL, infiltration of leukemic cells altered the homing sites of
healthy CD34+ progenitors (Colmone et al., 2008). BCR-ABL-
driven chronic myelogenous leukemia (CML) was reported to
alter the microenvironment and reduce the capacity to support
normal hematopoiesis (Schepers et al., 2013; Zhang et al.,
2012). Conversely, patient-derived mesenchymal stem and pro-
genitor cells (MSPCs) were shown in order to propagate thetem Cell 15, 365–375, September 4, 2014 ª2014 Elsevier Inc. 365
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Adrenergic Signals Regulate Acute Myelogenous Leukemiaexpansion of human myelodysplastic cells in xenografts (Me-
dyouf et al., 2014). However, the nature of the LSC niche remains
unclear.
Given the rapid and extensive remodeling imposed by AML
infiltration of the bone marrow, we anticipated that the mecha-
nisms of bone marrow regeneration might overlap with the
requirements ofAMLdevelopment. The importanceof SNSnerve
function in hematopoietic regeneration (Lucas et al., 2013) com-
bined with the requirement of SNS nerves for the development of
xenografted prostate cancer (Magnon et al., 2013), suggested
that the inhibition of adrenergic signals might curb AML develop-
ment. Unexpectedly, we report herein that MLL-AF9 AML
co-opts SNS fibers in the bone marrow and spleen and that
sympathetic neuropathy or adrenergic blockade promotes AML
through an expanded, but severely altered, stem cell niche.
RESULTS
Adrenergic Signals Regulate AML
We transduced Linc-Kit+Sca-1+ (LSK) cells with the MLL-AF9
oncogene and clonally propagated transduced LSK cells in
methylcellulose as preleukemic cells (Krivtsov et al., 2006).
Transplantation of transduced cells rapidly induced the disease
with massive bone marrow and spleen infiltration of monomor-
phic undifferentiated cells uniformly expressing myeloid cell
markers, without myelofibrosis (data not shown). Serial trans-
plantations enriched for stem cell activity and robust engraft-
ment could be reproducibly achieved with leukemic bone
marrow cells from tertiary recipients without the need for precon-
ditioning and avoiding the potential of irradiation-induced
changes in the microenvironment.
To assess the functional role of the SNS in AML, we ablated
adrenergic nerves of recipient mice with 6-hydroxydopamine
(6OHDA), which specifically disrupts catecholaminergic neurons
without directly affecting hematopoietic cells (Katayama et al.,
2006; Me´ndez-Ferrer et al., 2008). Surprisingly, we found that
mice with denervated bone marrow exhibited greater infiltration
by phenotypic LSCs, defined as IL-7RLinGFP+c-KithiCD34lo
FcgRII/IIIhi granulocyte-macrophage progenitors (L-GMPs) (Fig-
ures 1A and 1B), and significantly higher egress of L-GMPs to
peripheral blood and spleen than control animals (Figure 1C).
This was associated with a significant reduction in the survival
of denervated leukemic mice after transplantation of either pre-
leukemic or leukemic MLL-AF9 cells (Figures 1D; Figure S1AFigure 1. Sympathetic Neuropathy Promotes Leukemogenesis
(A) Gating strategy for flow cytometry analysis of LSC/L-GMPs.
(B) Absolute number of L-GMPs per femur in control and denervated leukemic m
(C) Absolute number of L-GMPs per ml blood (left) and spleen (right) in contro
control, n = 4–5).
(D) Survival curve of control and denervated leukemic mice (n = 5).
(E) Left, flow cytometry gating strategy for bone marrow analysis of human hemat
myeloid hCD33+ cells and excluding hCD3+ and hCD19+ expression (data not s
(BMT = bone marrow transplantation). Right, human myeloid bone marrow engra
denervated NSG mice (data are normalized to paired controls, n = 4 human AML
(F) Top, z stack confocal images from bone marrow, spleen, and cremaster mus
represents 10 mm. Bottom, assessment of the TH+ fiber density per arteriole by
responding arteriole (bone marrow: n = 33–49 arterioles from six to eight mice per
n = 16–17 arterioles from six mice per group). *p < 0.05, **p < 0.01 determined b
See also Figure S1.
Cell Savailable online). These significant differences in leukemia devel-
opment were due to neither a potential effect of denervation on
the homing of leukemic cells to bone marrow and spleen (Fig-
ure S1B) nor a direct effect on MLL-AF9 leukemia cells (Fig-
ure S1C). Furthermore, sympathetic denervation performed after
the leukemic cell injection significantly accelerated the course of
disease, indicating that adrenergic regulation of AML acted
beyond the engraftment period (Figure S1D). We did not observe
any difference between the two groups in cell cycle or apoptosis
of LSCs after transplantation (Figures S1E and S1F). Thus, bone
marrow infiltration by AML is increased when sympathetic inner-
vation is compromised.
To assess the relevance of adrenergic signals in human AML,
we transplanted primary human AML cells into denervated and
control NOD-scid IL2Rg/ mice. We observed a significantly
higher bone marrow infiltration with human myeloid cells in
denervated mice (Figure 1E), even when samples were derived
from myeloblastic or myelomonocytic leukemia (French-Amer-
ican-British classification AML M1 or M4), suggesting that the
SNS may affect AML outside the MLL-AF9+ monocytic subtype.
To get more insight into the effect of AML infiltration on the
HSC niche, we injected MLL-AF9 leukemic cells into Nes-Gfp+
mice in which GFP expression by perivascular cells marks
HSC niches (Me´ndez-Ferrer et al., 2010). After 3 weeks, we eval-
uated the bone marrow by immunofluorescence imaging of thick
sections in order to assess the vascular structures (Kunisaki
et al., 2013). Leukemic bonemarrow exhibitedmarked increases
in sinusoidal densities with a disorganized appearance (Fig-
ure 2F). Additionally, tyrosine hydroxylase (TH) staining, which
specifically labels catecholaminergic fibers, revealed a signifi-
cant reduction of arterioles covered by TH+ fibers in AML bone
marrow in comparison to healthy controls (data not shown).
Strikingly, the arterioles that remained innervated exhibited sig-
nificant reductions in the density of ensheathing TH+ fibers (Fig-
ure 1F, left). Sympathetic neuropathy was not confined to the
bone marrow but also occurred in the spleen, and this correlated
with reduced noradrenaline levels in these tissues (Figures 1F,
middle, and S1G). In contrast, adrenergic innervation of the
skeletal muscle, a site which is not primarily infiltrated by
leukemic cells, did not exhibit any significant change (Figure 1F,
right). These results indicate that leukemia development induces
sympathetic neuropathy at infiltrated sites, resulting in a locally
reduced sympathetic tone which in turn may reinforce the
leukemic disease.ice 20 days after transplantation (normalized to control, n = 19–20).
l and denervated leukemic mice 23 days after transplantation (normalized to
opoietic engraftment by gating on human (h) CD45+ cells detecting exclusively
hown). Representative flow cytometry plots from each experimental condition
ftment 4 weeks after transplantation of primary human AML cells in control or
samples).
cle stained for PECAM1+ endothelial cells and TH+ nerve fibers. The scale bar
quantifying the total length of all TH+ branches divided by the area of the cor-
group; spleen n = 21–29 arterioles from five mice per group; cremaster muscle:
y Student’s t test. Data are shown as mean ± SEM.
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Adrenergic Signals Regulate Acute Myelogenous LeukemiaBecause our recent studies have revealed that the denerva-
tion of healthy bone marrow can lead to increased numbers
of Nes-GFP+ cells (Lucas et al., 2013), we determined the con-
tent of stromal and endothelial cells with fluorescence-
activated cell sorting (FACS). We found a 3.8-fold expansion
of Nes-GFP+ bone marrow stromal (CD45CD11bTer119
CD31) MSPCs in leukemic mice (Figures 2A). Leukemic
bone marrow Nes-GFP+ cells retained their phenotypic charac-
teristics with similar proportion of LepR+, PDGFRa+, and CD51+
cells than healthy control mice (Figures 2B). The increased
numbers of PDGFRa+CD51+ MSPCs (Pinho et al., 2013)
confirmed that the higher proportion of Nes-GFP+ cells was
not due to an effect of the leukemia on the Nes promoter activ-
ity (Figure 2C). MSPCs exhibited a significant loss of quies-
cence, suggesting that their increased numbers were most
likely due to proliferation (Gronthos et al., 2003; Kunisaki
et al., 2013) (Figure 2D).
The loss of quiescence resulted in a higher vulnerability to gen-
otoxic insult. In control mice, sublethal irradiation can induce
adipogenesis in the bone marrow (Bryon et al., 1979), through
differentiation from MSPCs (Mizoguchi et al., 2014). However,
in leukemic mice, the number of MSPCs was significantly
reduced after irradiation, resulting in reduced numbers of
Perilipin+ adipocytes (Figure 2E). In line with increased vascular
densities (Figure 2F) (see also Aguayo et al., 2000; Hussong
et al., 2000; Padro´ et al., 2000), leukemic bonemarrow contained
increased numbers of endothelial cells as determined by flow
cytometry (Figure 2F) and cell-cycle analyses also revealed a
reduction of the quiescent fraction (Figures 2G). These results
indicate that leukemic bone marrow infiltration leads to MSPC
and endothelial cell expansion associated with SNS denervation.
Expanded Nes-GFP+ Cells Are Directed Toward the
Osteoblastic Lineage
We assessed the function of mesenchymal lineages in leukemic
bone marrow. Purified Nes-GFP+ cells from leukemic marrow
contained a 1.7-fold greater fibroblastic colony-forming unit
(CFU-F) capacity in comparison to healthy controls (Figure 3A)
but remained confined within the Nes-GFP+ stromal population
(data not shown). To assess the commitment of Nes-GFP+ cells
to differentiate to the osteoblastic lineage, we stimulated osteo-
blast differentiation and mineralization in isolated Nes-GFP+
bone marrow cells. We found a significant increase in the num-
ber of osteoblastic colony-forming units (CFU-OB) with largerFigure 2. Bone Marrow MSPCs and Endothelial Cells Significantly Exp
(A) Left, representative flow cytometry plots, gated on stromal (CD45Ter119
leukemic mice. Middle and right, frequency and absolute numbers of Nes-GFP+
(B) Summary of mesenchymal surface marker screening expressed by stromal
controls (gray columns) as detected by flow cytometry analysis (n = 3–10).
(C) Representative flow cytometry plots and quantification of PDGFRa and CD51
(D) Cell-cycle analysis of PDGFRa and CD51 double-positive bone marrow stroma
and Hoechst 33342 staining (n = 3).
(E) Top, z stack confocal images of thick bone sections stained with anti-Perilipin
PDGFRa and CD51 double-positive bone marrow stromal cells (left, normalized t
growth plate (right) 6 days after sublethal irradiation (n = 4).
(F) Left, frequency of nonhematopoietic (CD45Ter119) CD31+ endothelial cells (
anti-PECAM1 and VE-cadherin antibodies. The magnified confocal images withi
(G) Cell-cycle analysis of endothelial cells quantified by flow cytometry with ant
determined by Student’s t test. Data are shown as mean ± SEM.
Cell Smineralizing colonies, indicating that Nes-GFP+ cells in leukemic
bone marrow have an enhanced commitment toward osteo-
blastic differentiation (Figures 3B and 3C). A subset of leukemic
bone-marrow-derived Nes-GFP+ cells showed multilineage dif-
ferentiation capacity after >30 days in culture (Figure S2A). In
line with these data, the number of immature and mature osteo-
lineage cells from the compact bone, measured as CD51+/
Sca-1 stromal cells (Winkler et al., 2010), were significantly
increased in AML (Figure 3D). However, we found that tartrate-
resistant acid phosphatase (TRAP)+ osteoclast numbers in the
metaphysis of the tibiae of diseased leukemic mice were
reduced (Figure 3E). To morphologically characterize these
osteolineage cells, we transplanted Osterix (Osx)-creERT2/loxp-
tdTomato mice with MLL-AF9 leukemic cells. Consistent with
prior analyses, Cre-mediated recombination in 8-week-old
adults was restricted to osteolineage cells (Park et al., 2012).
Because of the rapid turnover of Osx-recombined preosteo-
blasts, we continuously administered tamoxifen via a chow
diet. Although healthy controls exhibited robust labeling of
cuboidal bone-lining cells, the number of mature cuboidal oste-
oblasts in leukemic mice were markedly decreased (Figures 3F
and S2B). In addition, we observed in the endosteal region of
leukemic mice a striking accumulation of reticular Osx-marked
cells with cellular extensions toward endothelial cells (Figure 3F)
similar to previously described osteoblast precursors in devel-
oping bone and in fracture healing (Maes et al., 2010). These
reticular Osx-labeled cells from leukemic marrow expressed
LepR, unlike mature osteoblast from healthy mice (Figures 3G,
3H, and S2C), but lacked osteocalcin expression (Figures 3I
and S2D). The decrease in mature osteoblasts in leukemic
mice was reflected by significant reduction of mineralized
trabecular bone volumes as determined by micro-CT analyses
(Figures 3J–3L). Altogether, these results suggest that AML
leads to increased bone remodeling with accumulation of osteo-
blast-primed MSPCs accompanied by reduced numbers of
mature bone-forming osteoblasts.
AML Impairs HSC Niche Function
AML often leads to pancytopenia and reductions of normal he-
matopoiesis, but themechanisms remain unclear. Next, we eval-
uated the impact of AML infiltration on HSC niche function of the
bonemarrow. Sorted stromal PDGFRa+CD51+ leukemicMSPCs
expressed lower levels of Vcam1, Cxcl12, Angpt1, and Scf tran-
scripts in comparison to those of healthy controls (Figure 4A). Inand in AML
CD11bCD31) bone marrow cells, showing Nes-GFP+ cells in control and
cells per femur (n = 9–10).
Nes-GFP+ bone marrow cells from leukemic mice (red columns) and healthy
double-positive bone marrow stromal cells (n = 9–15).
l cells; representative plots and quantification by flow cytometry with anti-Ki67
and Hoechst 33342. The scale bar represents 300 mm. Bottom, frequency of
o control) and quantification of Perilipin+ adipocytes in 0.5 mm2 area under the
n = 6). Right, z stack confocal images of thick bone sections stained in vivo with
n the area were defined by the rectangle. The scale bar represents 500 mm.
i-Ki67 and Hoechst 33342 staining (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001
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Adrenergic Signals Regulate Acute Myelogenous Leukemiacontrast, Opn expression was increased in bone marrow
MSPCs, which is in accordance with their propensity to differen-
tiate into the osteoblastic lineage. In addition, the number of rare
pericytic NG2+ cells associated with HSC quiescence and main-
tenance (Kunisaki et al., 2013) were significantly reduced in
leukemic mice (Figures 4B and S3A–S3C). Notably, the reduc-
tion of NG2+ cells was not likely due to increased differentiation
to the more abundant PDGFRa and CD51 double-positive
MSPC population, given that they were not fate mapped by
NG2-creERTM/loxp-tdTomato mice (Figures S3A and S3D).
Consistent with reduced numbers of periarteriolar NG2+ cells
and lower levels of HSC-regulating genes, phenotypic long-
term HSCs initially expanded, but were then significantly
reduced, in the bone marrow of leukemic mice (Figures 4C and
S3E). The reduction of functional HSCs and hematopoietic pro-
genitor cells in the bonemarrowwas confirmed by long-term cul-
ture-initiating cell (LTC-IC) assays (Figures 4D and 4E), CFU-Cs
and phenotypic progenitors (Figures 4G and S3G), and compet-
itive repopulation assays (Figure S3F). The reduced expression
of HSC maintenance and retention genes (Figure 4A) in Nes+
cells led to significant mobilization of phenotypic HSCs and
colony-forming progenitors to the circulation and the spleen
(Figures 4F, S3H, and S3I). In addition, whole-mount imaging
analyses revealed that bone marrow HSCs were displaced
away from arterioles (Figure 4H). Thus, these results strongly
suggest that AML severely alters the niche, leading to reduced
ability to maintain healthy HSC in the bone marrow.
Stromal b2 Adrenergic Receptors Regulate LSCs
Previous studies have shown that the SNS regulates bone for-
mation through b2 adrenergic receptors expressed on osteo-
blasts (Elefteriou et al., 2005; Takeda et al., 2002), whereas b3
adrenergic signaling appears to play a more prominent role in
regulating the healthy HSC niche (Me´ndez-Ferrer et al., 2008).
Consistent with the enhanced osteolineage differentiation of
MSPCs in AML, the expression of the Adrb3 in PDGFRa+CD51+
stromal cells was significantly reduced in comparison to healthy
mice, whereas the Adrb2 expression remained unchanged (Fig-
ure S4A). To get additional mechanistic insight into SNS regula-
tion of leukemia formation, we treated mice with specific Adrb2Figure 3. Bone Marrow Nes-GFP+ MSPCs Have Differentiated Toward
(A and B) StromalNes-GFP+ cells were sorted from control and leukemic bonema
culture conditions. Frequency of CFU-F (n = 6–7, in duplicate and triplicate permo
GFP+ cells.
(C) Representative images of CFU-OB colonies from Nes-GFP+ bone marrow ce
hematoxylin. The scale bar represents 500 mm.
(D) Absolute numbers of stromal CD51+/Sca-1 osteolineage cells in the compa
(E) Quantification of TRAP+ osteoclasts in the metaphyseal area (500 mm unde
measured bone surface (n = 3).
(F) Z stack confocal images of thick bone sections ofOsterix-creERT2/loxp-tdToma
area defined by the rectangle. Arrowhead indicates osteoblast precursors. Anti-P
(G and H) Z stack confocal images of thick bone sections of Osterix-creERT2/lox
denote LepR-expressing Osx-Cre/Tomato+ cells). The scale bar represents 20 m
(I) Z stack confocal images of thick bone sections ofOsterix-creERT2/loxp-tdToma
scale bar represents 50 mm.
(J) Micro-CT analysis of femurs from control and leukemic mice (n = 3). Analysis of
as trabecular number (right).
(K and L) Representativemicro-CT images of cortical (K) and trabecular (L) bone fro
t test. Data are shown as mean ± SEM.
See also Figure S2.
Cell S(ICI118,551) and Adrb3 (SR59230A) antagonists starting 3 days
prior to transplantation. We found that the inhibition of Adrb2,
but not Adrb3, significantly augmented the numbers of pheno-
typic LSCs in the bone marrow in comparison to control mice
(Figure 4I). Leukemic bonemarrow cells from ICI118,551-treated
mice exhibited significantly higher colony-forming capacity and
also formed significantly larger colonies, indicating greater prolif-
erative capacity (Figure S4B). Increased leukemic infiltration by
the blockade of Adrb2 was associated with significantly reduced
survival of leukemic mice (Figure 4J). Given that Adrb2 is also ex-
pressed on leukemic cells (data not shown), we sought to ascer-
tain whether sympathetic signals directly regulated AML cells or
whether the signals were mediated through the microenviron-
ment. To this end, we transplanted MLL-AF9 leukemic cells
(expressing the Adrb2) into Adrb2-deficient or -sufficient ani-
mals. We observed a significantly higher leukemic bone marrow
infiltration in Adrb2-deficient mice, suggesting a critical role
for Adrb2 expressed in the microenvironment (Figure 4K).
Conversely, the administration of an Adrb2 agonist (Clenbuterol
hydrochloride) led to a significant reduction of phenotypic LSCs
in bone marrow, spleen, and blood and tended to prolong sur-
vival (Figures 4L and S4C–S4E). However, Clenbuterol also
had a different cell-autonomous action, given that it enhanced
in vitro proliferation of MLL-AF9 cells (Figure S4F). Thus, these
results suggest that, although b2 agonist might rescue the
healthy niche to limit LSC expansion, it also has an opposite ac-
tion on leukemia cells that may mitigate its antileukemic effects.
DISCUSSION
Here, we show that MLL-AF9 AML rapidly transforms the HSC
niche, reducing the numbers of arteriole-associated NG2+ niche
cells and the density of their SNS nerve network, which is critical
for MSC quiescence. This leads to the expansion of Nes-GFP+
niche cells committed to differentiate toward the osteoblast line-
age with a block of differentiation to mature osteoblasts. The
high expression ofOpn by leukemic niche cells is also consistent
with osteoblastic commitment and may contribute to AML pro-
gression, as recently reported in an ALL model (Boyerinas
et al., 2013), and because the major Opn receptor, aVb3 integrin,the Osteoblastic Lineage
rrow and plated at equal numbers at clonal densities under CFU-F andCFU-OB
use; A) and CFU-OB (n = 4–5, in triplicate per mouse; B) from bonemarrowNes-
lls stained with alkaline phosphatase and von Kossa and counterstained with
ct bone (normalized to control, n = 5–8).
r the growth plate area) of the tibia. Number of TRAP+ cells in relation to the
to control and leukemicmice. Middle, themagnified confocal images within the
ECAM1 and VE-cadherin antibodies in vivo. The scale bar represents 500 mm.
p-tdTomato control (G) and leukemic (H) mice stained with anti-LepR (arrows
m.
to control (left) and leukemic (right) mice stained with osteocalcin antibody. The
cortical (left) and trabecular (middle) bone volume/total volume (BV/TV) as well
m control and leukemicmice. *p < 0.05, **p < 0.01 determined by the Student’s
tem Cell 15, 365–375, September 4, 2014 ª2014 Elsevier Inc. 371
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Adrenergic Signals Regulate Acute Myelogenous Leukemiais expressed by MLL-AF9 AML cells and was shown to be
required for leukemogenesis (Miller et al., 2013). Our results
suggest that sympathetic neuropathy represents a mechanism
by which AML co-opts the microenvironment to its own advan-
tage to deplete niche cells that maintain healthy HSCs and
expand leukemia-supportive, more differentiated, Nes+LepR+
Osx-creERT2-labeled mesenchymal progenitors. Finally, the
decreased sympathetic tone in bone marrow and spleen rein-
forces leukemia progression through an altered niche.
A recent study has suggested that the microenvironment of
leukemias can be differentially regulated wherein increased
osteoblastic function (by activation of the parathyroid hormone
receptor) is associated with progression of MLL-AF9 AML,
whereas BCR-ABL-driven disease was markedly attenuated
(Krause et al., 2013). It is notable that BCR-ABL CML blast
crisis—which resembles acute leukemia—led to significant re-
ductions of mature osteoblasts (Frisch et al., 2012), whereas in
a more chronic model of BCR-ABL CML, bone-forming mature
osteoblasts were reportedly increased (Schepers et al., 2013),
suggesting that AML andCMLmay have opposing effects on dif-
ferentiation to mature osteoblasts.
Our results shed light on the mechanisms by which MLL-AF9
AML cells remodel the bone marrow niche in order to create a
self-sustaining microenvironment at the expense of the mainte-
nance of healthy HSCs. Thus, manipulation of the adrenergic
system or other pathways that prevent mesenchymal differenti-
ation may provide a potentially powerful strategy for limiting LSC
development and preserving healthy HSCs.
EXPERIMENTAL PROCEDURES
Detailed procedures can be found in the Supplemental Experimental
Procedures.
Mouse Strains
All murine experiments were performed with adult 6- to 10-week-old animals.
All mice were housed in specific pathogen-free facilities at the Albert Einstein
College of Medicine animal facility, and all experimental procedures were
approved by the Animal Care and Use Committee of the Albert Einstein Col-Figure 4. Leukemic Bone Marrow Niche Has Impaired HSC-Regulating
(A) Gene expression analysis of key HSC-regulatory genes (Vcam1,Cxcl12, Angpt
time PCR (n = 5–6).
(B) Frequency of stromal NG2DsRed+ cells in the bone marrow (normalized to co
(C) Frequency of phenotypic LinSca-1+c-kit+Flt3CD34 long-term HSCs in leu
marrow infiltration (late) in comparison to matched control mice (n = 10, 5, and 8
(D) Quantification of long-term reconstituting HSCs by LTC-IC assay on sorted GF
frequency is given. Dashed lines represent 95% confidence interval.
(E) LTC-IC numbers per femur calculated with the frequency of MLL-AF9 GFP
(F) Absolute numbers of LinSca-1+c-kit+Flt3 (LSKF) cells in peripheral blood (left
and matched control mice.
(G) Left, CFU-C from 53 104 sorted MLL-AF9 GFP bone marrow (BM) cells. Rig
cells (n = 5–6).
(H) Representative whole-mount images and distribution of HSCs in the sternal bo
AML [late stage] group, respectively). Arrowheads denote HSCs. Two-sample K
(I) Absolute number of L-GMPs per femur in mice treated with the Adrb3-inhibito
after transplantation (normalized to control, n = 14–15).
(J) Survival curve of mice treated with ICI118,551 and control mice (n = 5).
(K) Frequency of leukemic cells per femur in Adrb2/ and control mice (n = 5–7
(L) Absolute number of L-GMPs per femur in mice treated with the Adrb2 agoni
plantation (normalized to control, n = 7–8). *p < 0.05, **p < 0.01, ***p < 0.001, ****p
See also Figures S3 and S4.
Cell Slege of Medicine. C57BL/6 mice were purchased from National Cancer Insti-
tute (Frederick Cancer Research Center). Cspg4-DsRed.T1 (NG2DsRed),
B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J (loxp-tdTomato), and B6.Cg-
Tg(Cspg4-cre/Esr1*)BAkik/J (NG2-creERTM) mice were purchased from the
Jackson Laboratory. Nes-Gfp transgenic mice (Mignone et al., 2004) and
NOD-scid Il2Rg/ (NSG) mice were bred and used at the Albert Einstein
College ofMedicine.Osx-creERT2mice (Maes et al., 2010) were kindly provided
by Dr. Henry M. Kronenberg and backcrossed for five generations into
C57BL/6 background. Adrb2tm1Bkk were a gift from Dr. Gerard Karsenty.
In Vivo Treatments
For induction of Cre-mediated recombination in Osx-CreERT2 mice, chow
diet (Harlan Laboratories) containing tamoxifen (Sigma-Aldrich) at 750 mg/kg
with 5% sucrose was given. For induction of Cre-mediated recombination in
NG2-CreERTM mice, 1 mg tamoxifen (Sigma-Aldrich) was injected twice daily
for 5 consecutive days as previously described (Kunisaki et al., 2013). For
denervation experiments, 6OHDA was intraperitoneally (i.p.) given at 24 hr
(100 mg/kg) and 72 hr (250 mg/kg) after transplantation unless otherwise
stated. The b2-specific antagonist ICI 118,551 hydrochloride (1 mg/kg body
weight i.p.) and the b3-specific antagonist SR59230A (5 mg/kg body weight
i.p.) were given daily beginning 3 days prior to transplantation, and Clenbuterol
hydrochloride (2 mg/kg body weight s.c.) was given daily 3 days after trans-
plantation (all from Sigma-Aldrich).
Statistical Analyses
All data are shown as themean ± SEM. Unless otherwise indicated for compar-
isons between two groups, the Student’s t test was applied. Log-rank analyses
were used for Kaplan-Meier survival curves. Analyses were performed with
GraphPad Prism software. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.stem.2014.06.020.
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